Where Chinese Investors Meet Global Investment News and Opportunities

中國投資者探索環球投資新聞及機遇

Redhill Biopharma Ltd (NASDAQ:RDHL)

Summary

RedHill Biopharma Ltd. is a NASDAQ listed drug manufacturer based in Israel. The company is focused on late clinical-stage, orally-administered drugs for the treatment of internal inflammatory disorders such as gastroenteritis.

Market Overview

$0.00 (-3.630%)
Vol 0.00
10 Days Avg Vol 0.00
3 Mo Avg Vol 80,552.57
52 Wk Lo/Hi $8.16 - $15.93
YTD Price Gain % -100%
12 Wks Moving Avg 9.332097
200 Days Moving Avg 9.870094
Market Cap 0

Company Background

RedHill Biopharma Ltd. is an Israel-based developer of pharmaceutical products addressing multiple diseases. Its primary focus lies on late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of internal inflammatory disorders and cancer. Redhill's assortment of drugs includes RHB-105, which combats the Helicobacter pylori infection; RHB-104, which treats the Crohn's disease and RIZAPORT, for acute migraines. The BEKINDA, YELIVA and MESUPRON were formulated for acute gastroenteritis and other critical inflammatory conditions.

Highlights

Other Information

Management Profiles

No management profiles found.